Taro Pharmaceutical Industries Securities Litigation
Up to $2.53
This settlement is closed to new claims — the deadline was August 16, 2024. You can still see what it was about and follow the case in court below. Looking for money you can still claim? Browse open settlements →
What happened
Taro Pharmaceutical Industries Ltd. and individual defendants Michael Kalb and Kalyanasundaram Subramanian were accused of securities violations in connection with Taro common stock. The defendants deny wrongdoing. They agreed to settle the class action by creating a $36 million fund to compensate eligible investors.
Do you qualify?
Anyone who purchased Taro common stock on the open market on a U.S. stock exchange from July 2, 2014 through November 3, 2016. Excluded are defendants, Taro Pharmaceuticals USA Inc., Sun Pharmaceutical Industries Ltd., and their officers, directors, family members, and entities with majority ownership by them.
How to file
Submit a Claim Form by August 16, 2024 to be eligible for payment. The Claim Form must include documentation of your purchase and loss. Contact the Claims Administrator at 855-208-4121 or info@TaroSecuritiesLitigation.com for the form and instructions.
Common questions
- How much does the Taro Pharmaceutical Industries Securities Litigation pay?
- Estimated payout: Up to $2.53. The total settlement fund is $36M. Actual amounts depend on how many valid claims are filed — most settlements divide a fixed fund pro rata, so a higher claim rate means a smaller individual check. An "up to" figure is a cap, not a guarantee.
- What is the claim deadline for the Taro Pharmaceutical Industries Securities Litigation?
- This settlement is closed to new claims — the deadline was August 16, 2024. Once a claim deadline passes you generally forfeit your share, even if you qualified.
- Do I need proof of purchase for the Taro Pharmaceutical Industries Securities Litigation?
- Yes. This settlement asks for documentation supporting your claim — a receipt, an account record, or the notice you were sent. Check the official settlement website for exactly which documents are accepted.
- Is the Taro Pharmaceutical Industries Securities Litigation notice real, or a scam?
- JND Legal Administration is the settlement administrator for this case. Claims are filed at tarosecuritieslitigation.com. Filing a class action claim is always free — no legitimate settlement charges you to claim, and no administrator will ask for payment, a gift card, or your full Social Security number by email or text. If a notice asks for any of those, it is not from the administrator. When in doubt, ignore the link you were sent and go to the official settlement website directly.
- When will payments from the Taro Pharmaceutical Industries Securities Litigation be sent?
- Class action payouts typically take 12 to 24 months after the claim deadline, and longer if the settlement is appealed. The final approval hearing for this case is set for August 23, 2024; no payments can be issued before a settlement receives final approval.
New to class actions?
This summary was generated from public settlement documents and may contain errors. Confirm eligibility, deadlines, and payment terms on the official settlement website before filing. ClaimWatch is not a law firm and this is not legal advice. Filing a claim is free.
More securities settlements
View all →Tattooed Chef Securities Settlement
Tattooed Chef, Inc. faced a securities lawsuit alleging that purchasers of the company's common stock were damaged. The defendant has agreed to settle all claims in the action for $4,750,000 in cash without admitting wrongdoing.
Estée Lauder Securities Settlement
Estée Lauder is settling securities litigation relating to alleged damages to investors who purchased or acquired publicly traded common stock of The Estée Lauder Companies Inc. during the class period. The defendant has not admitted wrongdoing in this settlement.
E-Commerce China Dangdang Securities Settlement
E-Commerce China Dangdang, Inc. was involved in a take-private transaction (merger) that closed on September 20, 2016. Shareholders who held American Depositary Shares during the Class Period claim they were harmed by undisclosed information related to the Company's take-private transaction. The defendant has agreed to settle these securities claims without admitting wrongdoing.
Evolv Technologies Holdings Securities Settlement
Investors purchased publicly traded common stock of Evolv Technologies Holdings Inc. during a specific period and are entitled to compensation from a securities class action settlement. The page does not explicitly state what wrongdoing Evolv allegedly committed.